Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 known ✓ | O43614 | 1/20 | 0.40 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866198 | 0.99 | CYP1A2 (1.00) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9585626 | 0.88 | PMP22 (0.78) | LMNAPMP22CYP1A2CYP3A4THPO | |
| SCHEMBL9586457 | 0.87 | CYP1A2 (0.79) | LMNAPMP22CYP1A2CYP3A4THPO | |
| SCHEMBL9586019 | 0.87 | CYP1A2 (0.78) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9586889 | 0.86 | PMP22 (0.76) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9586218 | 0.86 | PMP22 (0.76) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9585902 | 0.86 | LMNA (0.76) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9586737 | 0.86 | PMP22 (0.76) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9586454 | 0.86 | PMP22 (0.75) | LMNAPMP22CYP1A2CYP3A4THPO | |
| Hydrochloric Acid SCHEMBL9585703 | 0.85 | PMP22 (0.74) | LMNAPMP22CYP1A2CYP3A4THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635667-B2 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2003-10-21 | — | — | US | claimed |
| US-20020128299-A1 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2002-09-12 | — | — | US | claimed |
| US-6432991-B1 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2002-08-13 | — | — | US | claimed |
| EP-1052983-A2 | USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS | Thomas, Thomas N. (US) | 2000-11-22 | — | — | EP | claimed |
| WO-1999037293-A2 | USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS | THOMAS THOMAS N (US) | 1999-07-29 | — | — | WO | claimed |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | 2A BIOSCIENCES, INC. | 2025-11-20 | — | — | US | disclosed |
| US-20250339496-A1 | SYSTEMS AND METHODS FOR SYMPATHETIC CARDIOPULMONARY NEUROMODULATION | TULAVI THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3288626-B1 | SUBSTANCES AND COMPOSITIONS FOR USE IN BLOCKING NERVE REGENERATION | REFLEX MEDICAL INC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250288728-A1 | SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION | TULAVI THERAPEUTICS INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-6635667-B2 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2003-10-21 | — | — | US | disclosed |
| US-20020128299-A1 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2002-09-12 | — | — | US | disclosed |
| US-6432991-B1 | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | THOMAS THOMAS N (US) | 2002-08-13 | — | — | US | disclosed |
| EP-1052983-A2 | USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS | Thomas, Thomas N. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999037293-A2 | USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS | THOMAS THOMAS N (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5204482-A | Ethylenediamine monoamide heteroaryl derivatives | HOFFMAN-LAROCHE INC. (US) | 1993-04-20 | — | — | US | disclosed |
| US-5011849-A | Monoamine oxidase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0352581-A2 | Ethylene diaminmonoamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | HCRTR2 51/4885ITGB3 4121/4885ITGA2B 4394/4885 |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | HTR5A, PNMT, HTR6 | HCRTR2 331/4885ITGB3 3699/4885ITGA2B 3553/4885 |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | HCRTR2 43/4885ITGB3 3261/4885ITGA2B 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.